Abstract l-DOPA is the standard treatment for Parkinson's disease (PD), but chronic
treatment typically leads to abnormal involuntary movement or dyskinesia (LID) …

L-DOPA is the standard treatment for Parkinson's disease (PD), but chronic treatment
typically leads to L-DOPA-induced dyskinesia (LID). LID involves a complex interaction …

Although dopamine replacement therapy with L-DOPA in Parkinson's disease initially
reduces motor symptoms, its chronic use often leads to the development of abnormal …

Long‐term dopamine replacement therapy with l‐DOPA in Parkinson's disease often leads
to the development of abnormal involuntary movements known as l‐DOPA‐induced …

Dopamine (DA) replacement therapy with l-DOPA is the standard treatment for Parkinson's
disease (PD). Unfortunately chronic treatment often leads to the development of abnormal …

J. Neurochem.(2010) 112, 1465–1476. Abstract l‐DOPA‐induced dyskinesia in Parkinson's
disease is associated with large increases in brain dopamine (DA) levels following drug …

Background: The serotonin (5-HT) system can manipulate the processing of exogenous L-
DOPA in the DA-denervated striatum, resulting in the modulation of L-DOPA-induced …

Pharmacological dopamine (DA) replacement with Levodopa [L-dihydroxyphenylalanine (L-
DOPA)] is the gold standard treatment of Parkinson's disease (PD). However, long-term L …

Serotonin transporter blockade with selective serotonin reuptake inhibitors (SSRIs) was
recently shown to counteract L-DOPA-induced dyskinesia in 6-hydroxydopamine (6-OHDA) …

To determine the role of norepinephrine transporter in reuptake of l‐DOPA‐derived
extracellular DA in the DA‐denervated Parkinsonian striatum, we examined extracellular DA …